Process Systems Enterprise (PSE) has formed an alliance—dubbed the Systems-Based Pharmaceutics Alliance—with pharmaceutical giant Pfizer that aims to develop a single model-based framework for drug substance manufacturing, drug product manufacturing, oral absorption, and pharmacokinetics. The alliance's goal will be to establish best practices in applying model-based techniques, which will be incorporated in computer software.
Systems-based pharmaceutics (SbP), according to PSE, is an holistic approach to developing and optimizing drug manufacture and drug delivery that could lead to faster development, more efficient R&D, and reduced cost and risk. It applies mathematic models of a manufacturing process to explore the design and operational decision space, allowing companies to make the best decisions for themselves in these areas based on key performance indicators. SbP's modeling approach, according to the firm, has worked well in other sectors including chemicals, clean energy, and consumer goods.
PSE adds that this alliance also includes a second unnamed major pharmaceutical company in addition to Pfizer. The firms are currently looking for more opportunities to partner with additional companies.